(Total Views: 699)
Posted On: 01/25/2023 6:11:51 PM
Post# of 148892
Merck announced they are halting a prostate cancer study. I’ll insert most of the article and link below. The point that caught my attention was this: “In addition to failing the primary endpoints, the Keytruda combo group experienced a greater amount of serious adverse events, according to the news release.”
I am too lazy to look it up, but wasn’t there talk quite some time ago about running a combo trial with Keytruda (Mexico)? If the company made a conscious decision not to do a combo with Keytruda, looks like a good move in hindsight.
Merck is slamming the brakes on a late-stage Keytruda study in prostate cancer after an interim analysis showed no improvement in survival, the company announced on Wednesday. However, the pharma giant cushioned the blow with a positive look at a separate study in biliary tract cancer.
An independent data monitoring committee reviewing the Phase III KEYNOTE-991 trial saw no improvement in overall survival or radiographic progression-free survival in a Keytruda combination group compared to the control group, Merck said in a news release. The trial was conducted in more than 1,200 patients with metastatic hormone-sensitive prostate cancer (mHSPC), or those whose cancer is controlled by keeping testosterone levels as low as would be expected after castration.
Researchers paired Keytruda with enzalutamide, sold by Astellas and Pfizer under the brand name Xtandi, and androgen deprivation therapy (ADT), while control patients received a placebo in combination with enzalutamide and ADT. The study wasn’t slated for completion until 2026, according to a federal register of clinical trials.
In addition to failing the primary endpoints, the Keytruda combo group experienced a greater amount of serious adverse events, according to the news release.
“Merck is informing study investigators of the decision and advises patients in the study to speak to their physician regarding treatment,” the company said.
The news comes on the heels of Keytruda’s late-stage fail in metastatic castration-resistant prostate cancer (mCRPC) back in August. More than 1,000 patients with mCRPC who did not respond to hormone therapy enrolled in the trial, dubbed KEYNOTE-921. However, Keytruda alongside chemotherapy failed to best chemotherapy alone in both overall and progression-free survival.
Scientists continue to test Keytruda in a handful of studies for mCRPC patients, Merck said on Wednesday.
https://endpts.com/merck-halts-prostate-cance...ct-cancer/
I am too lazy to look it up, but wasn’t there talk quite some time ago about running a combo trial with Keytruda (Mexico)? If the company made a conscious decision not to do a combo with Keytruda, looks like a good move in hindsight.
Merck is slamming the brakes on a late-stage Keytruda study in prostate cancer after an interim analysis showed no improvement in survival, the company announced on Wednesday. However, the pharma giant cushioned the blow with a positive look at a separate study in biliary tract cancer.
An independent data monitoring committee reviewing the Phase III KEYNOTE-991 trial saw no improvement in overall survival or radiographic progression-free survival in a Keytruda combination group compared to the control group, Merck said in a news release. The trial was conducted in more than 1,200 patients with metastatic hormone-sensitive prostate cancer (mHSPC), or those whose cancer is controlled by keeping testosterone levels as low as would be expected after castration.
Researchers paired Keytruda with enzalutamide, sold by Astellas and Pfizer under the brand name Xtandi, and androgen deprivation therapy (ADT), while control patients received a placebo in combination with enzalutamide and ADT. The study wasn’t slated for completion until 2026, according to a federal register of clinical trials.
In addition to failing the primary endpoints, the Keytruda combo group experienced a greater amount of serious adverse events, according to the news release.
“Merck is informing study investigators of the decision and advises patients in the study to speak to their physician regarding treatment,” the company said.
The news comes on the heels of Keytruda’s late-stage fail in metastatic castration-resistant prostate cancer (mCRPC) back in August. More than 1,000 patients with mCRPC who did not respond to hormone therapy enrolled in the trial, dubbed KEYNOTE-921. However, Keytruda alongside chemotherapy failed to best chemotherapy alone in both overall and progression-free survival.
Scientists continue to test Keytruda in a handful of studies for mCRPC patients, Merck said on Wednesday.
https://endpts.com/merck-halts-prostate-cance...ct-cancer/
(1)
(0)Scroll down for more posts ▼
